Latest news with #RigelPharmaceuticals
Yahoo
7 days ago
- Business
- Yahoo
H.C. Wainwright Reiterates a Buy Rating on Rigel Pharmaceuticals (RIGL), Sets a $57 PT
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is one of the top most undervalued biotech stocks to buy now. On August 6, analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) with a $57.00 price target. A researcher in a lab coat monitoring a biotechnological experiment. The analyst based the positive rating on the company's promising growth outlook and solid financial performance, stating that Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) reported an EPS of $3.28 in fiscal Q2 2025, exceeding both the firm's estimate of $2.52 and the consensus of $1.40. The company also surpassed expectations by reporting $101.7 million in total revenue in the quarter, attributed primarily to higher-than-expected revenue from Tavalisse. The analyst reasoned that Tavalisse benefited from enhanced access and higher patient starts after changes in Medicare Part D coverage. Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is a clinical-stage biotechnology company that discovers and develops targeted, novel drugs in oncology, immunology, and immune oncology. Its product portfolio includes Tavalisse, Fostamatinib, and R835. While we acknowledge the potential of RIGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Erreur lors de la récupération des données Connectez-vous pour accéder à votre portefeuille Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données
Yahoo
08-08-2025
- Business
- Yahoo
New Strong Buy Stocks for August 8th
Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today: InfuSystems Holdings INFU: This rapidly growing healthcare services company that provides state-of-the-art electronic continuous ambulatory infusion pumps, supplies and support to oncology practices and clinics throughout the United States, has seen the Zacks Consensus Estimate for its current year earnings increasing 66.7% over the last 60 day. InfuSystems Holdings, Inc. Price and Consensus InfuSystems Holdings, Inc. price-consensus-chart | InfuSystems Holdings, Inc. Quote Rigel Pharmaceuticals RIGL: This clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases, has seen the Zacks Consensus Estimate for its current year earnings increasing 19.1% over the last 60 days. Rigel Pharmaceuticals, Inc. Price and Consensus Rigel Pharmaceuticals, Inc. price-consensus-chart | Rigel Pharmaceuticals, Inc. Quote T. Rowe Price TROW: This global investment management company which provides a broad array of mutual funds, sub-advisory services and separate account management for individual and institutional investors, retirement plans and financial intermediaries, has seen the Zacks Consensus Estimate for its current year earningsincreasing 9.9% over the last 60 days. T. Rowe Price Group, Inc. Price and Consensus T. Rowe Price Group, Inc. price-consensus-chart | T. Rowe Price Group, Inc. Quote Mitsui & Co. MITSY: This global empire comprising more than 860 subsidiaries and associated companies with operations in chemicals, foodstuffs, general merchandise, iron and steel, machinery, nonferrous metals, textiles, energy, and real estate and service industries, has seen the Zacks Consensus Estimate for its current year earnings increasing 6% over the last 60 days. Mitsui & Co. Price and Consensus Mitsui & Co. price-consensus-chart | Mitsui & Co. Quote Northern Trust NTRS: This company which is a leading provider of wealth management, asset servicing, asset management and banking solutions to corporations, institutions, families, and individuals, has seen the Zacks Consensus Estimate for its current year earnings increasing 5.2% over the last 60 days. Northern Trust Corporation Price and Consensus Northern Trust Corporation price-consensus-chart | Northern Trust Corporation Quote You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Northern Trust Corporation (NTRS) : Free Stock Analysis Report T. Rowe Price Group, Inc. (TROW) : Free Stock Analysis Report Mitsui & Co. (MITSY) : Free Stock Analysis Report Rigel Pharmaceuticals, Inc. (RIGL) : Free Stock Analysis Report InfuSystems Holdings, Inc. (INFU) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
06-08-2025
- Business
- Yahoo
Rigel Pharmaceuticals Inc (RIGL) Q2 2025 Earnings Call Highlights: Record Revenue and Raised ...
Net Product Sales: $58.9 million, a 76% increase year over year. Total Revenue: $101.7 million, including $42.7 million in contract revenues from collaborations. Net Income: $59.6 million, compared to a net loss of $1 million in the same period in 2024. Cash Balance: $108.4 million at the end of the quarter. TAVALISSE Sales: $40.1 million, a 52% increase year over year. GAVRETO Sales: $11.8 million, with a 32% sequential growth from Q1 2025. REZLIDHIA Sales: $7 million, a 36% increase year over year. Revenue Guidance for 2025: Raised to $270 million to $280 million from the previous range of $200 million to $210 million. Net Product Sales Guidance for 2025: Increased to $210 million to $220 million from the prior range of $185 million to $192 million. Contract Revenues from Collaborations: Approximately $60 million, including $40 million in non-cash revenue from Lilly. Warning! GuruFocus has detected 4 Warning Signs with RIGL. Release Date: August 05, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Rigel Pharmaceuticals Inc (NASDAQ:RIGL) achieved net product sales of over $58 million in Q2 2025, marking a 76% increase year over year and the company's best quarter ever. Total revenue for the second quarter was $101.7 million, including $42.7 million in contract revenues from collaborations. The company reported a net income of $59.6 million for the second quarter, compared to a net loss of $1 million in the same period in 2024. Rigel Pharmaceuticals Inc (NASDAQ:RIGL) raised its total revenue guidance for 2025 to between $270 million and $280 million, reflecting anticipated growth of 45% to 52% compared to 2024. The company has a strong cash position, ending the quarter with cash, cash equivalents, and short-term investments of $108.4 million, up from $77.3 million at the end of 2024. Negative Points Rigel Pharmaceuticals Inc (NASDAQ:RIGL) decided not to exercise its right to share in future development expenses for ocadusertib, resulting in a $40 million non-cash revenue recognition. The company faces challenges in maintaining growth momentum, as the impact of improved patient affordability due to the Inflation Reduction Act may not be as strong in the second half of the year. There is uncertainty regarding the long-term growth trajectory beyond 2025, as the company has not provided guidance for future years. The company noted a change in status for one patient in the R289 study, previously reported as a responder, due to additional red cell transfusions not initially entered into the database. Rigel Pharmaceuticals Inc (NASDAQ:RIGL) continues to face competition and unmet needs in the lower-risk MDS market, with existing therapies only achieving around 38% to 40% transfusion independence rates. Q & A Highlights Q: Can you explain the factors contributing to the 52% growth in TAVALISSE sales? A: David Santos, Executive Vice President, Chief Commercial Officer: The growth was primarily driven by an increase in new patient starts, which was higher than ever before, and improved patient affordability in 2025 due to the elimination of the coverage gap by the Inflation Reduction Act. This allowed patients easier access to TAVALISSE, an oral agent, with a $2,000 annual out-of-pocket cap. Q: Is the 45% to 52% growth expectation for 2025 indicative of a new long-term growth trajectory for Rigel? A: Raul Rodriguez, President, Chief Executive Officer, Director: While we haven't provided guidance beyond 2025, the underlying business has been growing steadily. The dynamics that contributed to this year's growth, such as improved affordability and strong product performance, are expected to continue, but we remain focused on ensuring sustained growth. Q: What are the plans for the Phase 2 study in glioma, and how does the CONNECT study fit into your strategy? A: Lisa Rojkjaer, Executive Vice President, Chief Medical Officer: We will disclose more about the Phase 2 study design in recurrent glioma later this year. Regarding the CONNECT study, we are still discussing with CONNECT and potentially the agency about using the data to support a filing. We do not anticipate conducting an additional study in the same space. Q: How does the IRA impact your guidance for TAVALISSE and GAVRETO sales going forward? A: David Santos, Executive Vice President, Chief Commercial Officer: We expect continued growth in revenues, with improved affordability dynamics having a stronger impact in the first half of the year. The coverage gap issue was more pronounced at the beginning of the year, so we anticipate a lesser impact in the second half. Q: What is considered a clinically meaningful reduction in transfusion dependence for low-risk MDS patients? A: Lisa Rojkjaer, Executive Vice President, Chief Medical Officer: Current agents like luspatercept and imetelstat show an eight-week transfusion independence rate of around 38% to 40%. There is room for improvement, as many patients still do not benefit, and there are associated toxicities and administration inconveniences with these agents. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Yahoo
05-08-2025
- Business
- Yahoo
Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update
Second quarter 2025 total revenue of approximately $101.7 million, which includes net product sales of $58.9 million and contract revenues from collaborations of $42.7 million Completed enrollment in the dose escalation part of the ongoing Phase 1b study evaluating R289, a dual IRAK1/4 inhibitor, in patients with R/R lower-risk MDS Generated $59.6 million of net income in the second quarter of 2025 Updated 2025 Outlook: Total revenue of approximately $270 to $280 million, which includes net product sales of $210 to $220 million Total revenue and net income are inclusive of $40 million in non-cash contract revenue related to Rigel's agreement with Lilly Conference call and webcast scheduled today at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif., Aug. 5, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the second quarter ended June 30, 2025, including sales of TAVALISSE® (fostamatinib disodium hexahydrate), GAVRETO® (pralsetinib) and REZLIDHIA® (olutasidenib), and recent business progress. "Our strategic and disciplined approach to building our business has generated another strong quarter for the company. In the second quarter, we grew net product sales by 76% year-over-year, generated $59.6 million in net income and increased our cash balance to $108.4 million. This strong performance has enabled us to raise our 2025 financial guidance," said Raul Rodriguez, Rigel's president and CEO. "We're also excited by the continued advancement of our hematology and oncology development pipeline. In July, we completed enrollment in the dose escalation part of our ongoing Phase 1b study evaluating R289 in patients with relapsed or refractory lower-risk MDS. Later this year, we plan to share updated data from that study and initiate the dose expansion part of the study." Second Quarter 2025 Business Update Commercial Net product sales were $58.9 million, an increase of 76% from the same period of 2024. Rigel's partner Kissei Pharmaceutical Co., Ltd. (Kissei) announced that its licensing partner, JW Pharmaceutical Corporation, commercially launched TAVALISSE in South Korea in early July. Corporate In April, Rigel notified Eli Lilly and Company (Lilly) that it would not exercise its opt-in right related to the development and commercialization of ocadusertib (previously R552) for the treatment of non-central nervous system (CNS) diseases. As a result of the notification, Rigel recognized $40.0 million in non-cash revenue resulting from the release of the remaining cost share liability in the second quarter. Per the agreement with Lilly, Rigel will continue to be entitled to receive milestone and tiered royalty payments on future net sales of ocadusertib and the companies' CNS penetrant program. Clinical Development Rigel continues to advance its Phase 1b clinical study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of R2891, a novel and selective dual interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, in patients with relapsed or refractory (R/R) lower-risk myelodysplastic syndrome (MDS). Enrollment in the dose escalation part of the study was completed in July. The company expects to share updated data from the study later this year and plans to initiate the dose expansion part of the study in the second half of this year. Rigel presented 4 posters at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and 3 posters at the European Hematology Association (EHA) 2025 Congress. Presentations included the final data from the GAVRETO (pralsetinib) Phase 1/2 ARROW study in RET fusion-positive non-small cell lung cancer (NSCLC) and other solid tumors, and supportive data for REZLIHDIA (olutasidenib) in patients with mutated isocitrate dehydrogenase-1 (mIDH1) relapsed or refractory (R/R) acute myeloid leukemia (AML). Key Publications A paper titled "Effectiveness of Olutasidenib versus Ivosidenib in Patients With Mutated Isocitrate Dehydrogenase 1 Acute Myeloid Leukemia Who Are Relapsed or Refractory to Venetoclax: The 2102-HEM-101 Trial Versus a US Electronic Health Record-Based External Control Arm," was published in June by Catherine Lai, M.D., MPH, lead author and associate professor of Clinical Medicine, Division of Hematology-Oncology, Department of Medicine at University of Pennsylvania, in Leukemia & Lymphoma. A paper titled "Olutasidenib Alone or Combined with Azacitidine in Patients with Mutant IDH1 Myelodysplastic Syndrome," was published in July by Jorge E. Cortes, M.D., lead author and director, Georgia Cancer Center, Cecil F. Whitaker Jr., GRA Eminent Scholar Chair in Cancer, in Blood Advances. This is the first full report of the safety and clinical activity of an mIDH1 inhibitor plus hypomethylating agent (HMA) combination in patients with treatment-naïve and R/R MDS. The paper showed olutasidenib, alone or in combination with azacitidine, induced a high rate of clinically meaningful complete remission and hematologic improvement responses with durable remission duration, accompanied by low rates of serious treatment-emergent-adverse events in patients with intermediate-, high- or very high-risk MDS harboring mIDH1. Second Quarter 2025 and Year-to-Date Financial UpdateFor the second quarter ended June 30, 2025, total revenues were $101.7 million, consisting of $58.9 million in net product sales and $42.7 million in contract revenues from collaborations. Net product sales grew 76% compared to $33.5 million in the same period of 2024. TAVALISSE net product sales were $40.1 million, growth of 52% compared to $26.4 million in the same period of 2024. GAVRETO net product sales were $11.8 million compared to $1.9 million in the same period of 2024. GAVRETO became commercially available from Rigel in late June 2024. REZLIDHIA net product sales were $7.0 million, growth of 36% compared to $5.2 million in the same period of 2024. Contract revenues from collaborations primarily consisted of $40.0 million in non-cash revenue resulting from the release of the remaining cost share liability related to the agreement with Lilly for the development and commercialization of ocadusertib, $2.0 million of revenue from Grifols S.A. (Grifols) related to delivery of drug supplies and earned royalties, $0.4 million of revenue from Kissei related to the delivery of drug supplies, and $0.2 million of revenue from Medison Pharma (Medison) related to delivery of drug supplies and earned royalties. Total costs and expenses were $40.6 million compared to $36.4 million for the same period of 2024. The increase in costs and expenses was mainly due to higher cost of product sales, increased research and development costs driven by the timing of clinical activities related to olutasidenib and R289, and higher personnel-related costs and stock-based compensation expense. Rigel reported net income of $59.6 million, or $3.33 basic and $3.28 diluted per share, compared to a net loss of $1.0 million, or $0.06 basic and diluted per share, for the same period of 2024. For the six months ended June 30, 2025, total revenues were $155.0 million, consisting of $102.5 million in net product sales and $52.5 million in contract revenues from collaborations. Net product sales grew 72% compared to $59.5 million in the same period of 2024. TAVALISSE net product sales were $68.5 million, growth of 44% compared to $47.5 million in the same period of 2024. GAVRETO net product sales were $20.8 million compared to $1.9 million in the same period of 2024. GAVRETO became commercially available from Rigel in late June 2024. REZLIDHIA net product sales were $13.1 million, growth of 31% compared to $10.0 million in the same period of 2024. Contract revenues from collaborations primarily consisted of $40.0 million in non-cash revenue resulting from the release of the remaining cost share liability related to the agreement with Lilly for the development and commercialization of ocadusertib, $6.7 million of revenue from Grifols related to delivery of drug supplies and earned royalties, $5.1 million of revenue from Kissei related to a milestone payment and delivery of drug supplies and $0.6 million of revenue from Medison related to delivery of drug supplies and earned royalties. Total costs and expenses were $81.1 million compared to $72.9 million for the same period of 2024. The increase in costs and expenses was mainly due to higher cost of product sales, increased research and development costs driven by the timing of clinical activities related to olutasidenib and R289, and higher personnel-related costs. These increases were partially offset by decreased stock-based compensation expense primarily from performance-based stock awards. Rigel reported net income of $71.1 million, or $3.98 basic and $3.91 diluted per share, compared to a net loss of $9.3 million, or $0.53 basic and diluted per share, for the same period of 2024. Cash, cash equivalents and short-term investments as of June 30, 2025 was $108.4 million, compared to $77.3 million as of December 31, 2024. 2025 OutlookRigel is updating its 2025 total revenue guidance to approximately $270 to $280 million, an increase from the previous range of approximately $200 to $210 million, which includes: Net product sales of approximately $210 to $220 million, an increase from the previous range of approximately $185 to $192 million. Contract revenues from collaborations of approximately $60 million, an increase from the previous range of approximately $15 to $18 million. The company anticipates it will report positive net income for the full year 2025, while funding existing and new clinical development programs. The above total revenues and contract revenues from collaborations are inclusive of $40 million in non-cash contract revenue related to Rigel's agreement with Lilly. Conference Call and Webcast with Slides Today at 4:30pm Eastern TimeRigel will hold a live conference call and webcast today at 4:30pm Eastern Time (1:30pm Pacific Time). Participants can access the live conference call by dialing (877) 407-3088 (domestic) or (201) 389-0927 (international). The conference call will also be webcast live and can be accessed from the Investor Relations section of the company's website at The webcast will be archived and available for replay after the call via the Rigel website. About ITPIn patients with immune thrombocytopenia (ITP), the immune system attacks and destroys the body's own blood platelets, which play an active role in blood clotting and healing. Common symptoms of ITP are excessive bruising and bleeding. Patients suffering with chronic ITP may live with an increased risk of severe bleeding events that can result in serious medical complications or even death. Current therapies for ITP include steroids, blood platelet production boosters (TPO-RAs), and splenectomy. However, not all patients respond to existing therapies. As a result, there remains a significant medical need for additional treatment options for patients with ITP. About NSCLCIt is estimated that over 226,000 adults in the U.S. will be diagnosed with lung cancer in 2025. Lung cancer is the leading cause of cancer death in the U.S, with non-small cell lung cancer (NSCLC) being the most common type accounting for 85-90% of all lung cancer diagnoses.2 RET fusions are implicated in approximately 1-2% of patients with NSCLC.3 About AMLAcute myeloid leukemia (AML) is a rapidly progressing cancer of the blood and bone marrow that affects myeloid cells, which normally develop into various types of mature blood cells. AML occurs primarily in adults and accounts for about 1 percent of all adult cancers. The American Cancer Society estimates that there will be about 22,010 new cases in the United States, most in adults, in 2025.4 Relapsed AML affects about half of all patients who, following treatment and remission, experience a return of leukemia cells in the bone marrow.5,6 Refractory AML, which affects between 10 and 40 percent of newly diagnosed patients, occurs when a patient fails to achieve remission even after intensive treatment.7 Quality of life declines for patients with each successive line of treatment for AML, and well-tolerated treatments in relapsed or refractory disease remain an unmet need. About TAVALISSE®TAVALISSE (fostamatinib disodium hexahydrate) tablets is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Please click here for Important Safety Information and Full Prescribing Information for TAVALISSE. About GAVRETO®GAVRETO is indicated for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA-approved test and adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).* *Thyroid indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). Please click here for Important Safety Information and Full Prescribing Information for GAVRETO. About REZLIDHIA®REZLIDHIA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Please click here for Important Safety Information and Full Prescribing Information, including Boxed WARNING, for REZLIDHIA. To report side effects of prescription drugs to the FDA, visit or call 1-800-FDA-1088 (800-332-1088). TAVALISSE, GAVRETO and REZLIDHIA are registered trademarks of Rigel Pharmaceuticals, Inc. About RigelRigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit R289 is an investigational compound not approved by the FDA. The American Cancer Society. Key Statistics for Lung Cancer. Revised January 16, 2025. Accessed March 31, 2025: Kato, S. et al. RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients. Clin Cancer Res. 2017;23(8):1988-1997 doi: 10.1158/ The American Cancer Society. Key Statistics for Acute Myeloid Leukemia (AML). Revised March 4, 2025. Accessed March 31, 2025: Patel, A, et al. Outcomes of Patients With Acute Myeloid Leukemia Who Relapse After 5 Years of Complete Remission. 2021 Sep 7;28(7):811-814. doi: Thol F, Ganser, A. Treatment of Relapsed Acute Myeloid Leukemia. Curr. Treat. Options on Oncol. (2020) 21: 66. doi: Thol F, Schlenk RF, Heuser M, Ganser A. How I treat refractory and early relapsed acute myeloid leukemia. Blood (2015) 126 (3): 319-27. doi: Forward Looking StatementsThis press release contains forward-looking statements relating to, among other things, expected commercial and financial results, projected financial performance and outlook for 2025, expectations for growing our commercial business, potential investment in our pipeline, continued advancement and updated results of the dose escalation portion of our R289 study, continued ability for developing and commercializing TAVALISSE, GAVRETO, and REZLIDHIA domestically and in certain international markets, and expectations for Rigel's partnering and collaboration efforts. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements can be identified by words such as "anticipates", "plan", "outlook", "potential", "may", "look to", "expects", "will", "initial", "promising", and similar expressions in reference to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on Rigel's current beliefs, expectations, and assumptions and hence they inherently involve significant risks, uncertainties and changes in circumstances that are difficult to predict and many of which are outside of our control. Therefore, you should not rely on any of these forward-looking statements. Actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with the commercialization and marketing of fostamatinib, olutasidenib and pralsetinib; risks that the FDA, European Medicines Agency, PMDA or other regulatory authorities may make adverse decisions regarding fostamatinib, pralsetinib or olutasidenib; risks that clinical trials may not be predictive of real-world results or of results in subsequent clinical trials; risks that fostamatinib, pralsetinib or olutasidenib may have unintended side effects, adverse reactions or incidents of misuses; the availability of resources to develop Rigel's product candidates; market competition; as well as other risks detailed from time to time in Rigel's reports filed with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 and subsequent filings. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. Rigel does not undertake any obligation to update forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein, except as required by law. Contact for Investors & Media: Investors:Rigel Pharmaceuticals, Inc.650.624.1232ir@ Media:David RosenArgot RIGEL PHARMACEUTICALS, INC STATEMENTS OF OPERATIONS (in thousands, except per share amounts) Three Months Ended June 30,Six Months Ended June 30, 2025202420252024 (unaudited) Revenues: Product sales, net $ 58,948$ 33,450$ 102,498$ 59,453Contract revenues from collaborations 42,7373,39152,5206,922Total revenues 101,68536,841155,01866,375 Costs and expenses: Cost of product sales 4,5042,8078,9134,832Research and development (see Note A) 6,8215,54015,25711,566Selling, general and administrative (see Note A) 29,25728,04756,97256,496 Total costs and expenses 40,58236,39481,14272,894 Income (loss) from operations 61,10344773,876(6,519)Interest income 7535521,3441,145Interest expense (1,874)(2,029)(3,727)(3,903) Income (loss) before income taxes 59,982(1,030)71,493(9,277) Provision for income taxes 369—434— Net income (loss) $ 59,613$ (1,030)$ 71,059$ (9,277)Net income (loss) per share Basic $ 3.33$ (0.06)$ 3.98$ (0.53)Diluted $ 3.28$ (0.06)$ 3.91$ (0.53) Weighted average shares used in computing net income (loss) per share Basic 17,88517,54917,84817,534Diluted 18,16217,54918,16817,534Note AStock-based compensation expense included in: Selling, general and administrative $ 2,759$ 2,223$ 5,211$ 6,707Research and development 5173051,389955 $ 3,276$ 2,528$ 6,600$ 7,662 SUMMARY BALANCE SHEET DATA (in thousands)As of June 30,As of December 31, 20252024 (1) (unaudited) Cash, cash equivalents and short-term investments $ 108,378$ 77,321 Total assets 206,736163,976 Stockholders' equity 81,9343,288 (1) Derived from audited financial statements View original content to download multimedia: SOURCE Rigel Pharmaceuticals, Inc.
Globe and Mail
05-08-2025
- Business
- Globe and Mail
RIPK1 Inhibitor Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight
RIPK1 Inhibitor pipeline constitutes 10+ key companies continuously working towards developing 12+ RIPK1 Inhibitor treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. ' RIPK1 Inhibitor Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the RIPK1 Inhibitor Market. The RIPK1 Inhibitor Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. Some of the key takeaways from the RIPK1 Inhibitor Pipeline Report: Companies across the globe are diligently working toward developing novel RIPK1 Inhibitor treatment therapies with a considerable amount of success over the years. RIPK1 Inhibitor Key players such as - Sanofi, Genfleet Therapeutics, Rigel Pharmaceuticals, GlaxoSmithKline, AbbVie, Sanofi, Voronoi, Boston Pharmaceuticals, Sironax, Nuevolution, and others, are developing therapies for the RIPK1 Inhibitor treatment RIPK1 Inhibitor Emerging therapies such as - SAR443122, GFH312, R552, and others are expected to have a significant impact on the RIPK1 Inhibitor market in the coming years. In May 2025, Accropeutics' investigational drug has successfully met the primary objectives in a Phase 2 clinical trial for psoriasis conducted in China, leading the company to commit to accelerating the clinical advancement of its TYK2/JAK1 inhibitor, AC-201. In the trial, 145 Chinese patients with moderate to severe plaque psoriasis were administered one of three doses of AC-201 or a placebo. All dosing groups achieved the primary endpoint, with a significantly higher proportion of patients reaching a 75% improvement in their Psoriasis Area and Severity Score (PASI 75) at Week 12 compared to the placebo group. In October 2024, Sanofi discontinued its Phase 2 clinical trial of oditrasertib, an experimental RIPK1 inhibitor, in patients with relapsing and progressive multiple sclerosis (MS) after the treatment did not achieve its primary objectives. Initiated early last year, the trial failed to demonstrate a significant reduction in neurofilament light chain (NfL) levels — a biomarker associated with neurodegeneration. Additionally, the therapy did not meet any major secondary endpoints, as noted in a recent SEC filing by Denali Therapeutics, Sanofi's development partner. RIPK1 Inhibitor Overview A RIPK1 inhibitor is a type of drug that blocks the activity of Receptor-Interacting Serine/Threonine-Protein Kinase 1 (RIPK1) — an enzyme involved in regulating inflammation, cell death (especially necroptosis), and immune responses. Overactivation of RIPK1 has been linked to several diseases, including autoimmune disorders, neurodegenerative conditions, and inflammatory diseases. By inhibiting RIPK1, these drugs aim to reduce excessive inflammation and tissue damage, offering a promising therapeutic strategy for conditions like multiple sclerosis, Alzheimer's disease, and psoriasis. Emerging RIPK1 Inhibitor Drugs Under Different Phases of Clinical Development Include: RIPK1 Inhibitor Pipeline Therapeutics Assessment RIPK1 Inhibitor Assessment by Product Type RIPK1 Inhibitor By Stage and Product Type RIPK1 Inhibitor Assessment by Route of Administration RIPK1 Inhibitor By Stage and Route of Administration RIPK1 Inhibitor Assessment by Molecule Type RIPK1 Inhibitor by Stage and Molecule Type DelveInsight's RIPK1 Inhibitor Report covers around 12+ products under different phases of clinical development like Late-stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of Administration Download Sample PDF Report to know more about RIPK1 Inhibitor drugs and therapies RIPK1 Inhibitor Pipeline Analysis: The RIPK1 Inhibitor pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the RIPK1 Inhibitor treatment with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for RIPK1 Inhibitor Treatment. RIPK1 Inhibitor key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. RIPK1 Inhibitor Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the RIPK1 Inhibitor market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Scope of RIPK1 Inhibitor Pipeline Drug Insight Table of Contents 1 RIPK1 Inhibitor Report Introduction 2 RIPK1 Inhibitor Executive Summary 3 RIPK1 Inhibitor Overview 4 RIPK1 Inhibitor- Analytical Perspective In-depth Commercial Assessment 5 RIPK1 Inhibitor Pipeline Therapeutics 6 RIPK1 Inhibitor Late Stage Products (Phase II/III) 7 RIPK1 Inhibitor Mid Stage Products (Phase II) 8 RIPK1 Inhibitor Early Stage Products (Phase I) 9 RIPK1 Inhibitor Preclinical Stage Products 10 RIPK1 Inhibitor Therapeutics Assessment 11 RIPK1 Inhibitor Inactive Products 12 Company-University Collaborations (Licensing/Partnering) Analysis 13 RIPK1 Inhibitor Key Companies 14 RIPK1 Inhibitor Key Products 15 RIPK1 Inhibitor Unmet Needs 16 RIPK1 Inhibitor Market Drivers and Barriers 17 RIPK1 Inhibitor Future Perspectives and Conclusion 18 RIPK1 Inhibitor Analyst Views 19 Appendix 20 About DelveInsight About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
